Matthew Mei

30PUBLICATIONS

100CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursImmunogenetics (incl. genetic immunology)HaematologyTransplantation immunology

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (30)

Sort by Publication Date:

|Jun 25, 2026

Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin.

|Mar 18, 2026

Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell Lymphoma.

Geoffrey Shouse, Matthew Matasar, Lu Chen

|Dec 17, 2025

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma.

Sanjal H Desai, Alison J Moskowitz, Reid W Merryman

|Nov 19, 2025

Mosunetuzumab is effective and well tolerated in older patients with relapsed/refractory follicular lymphoma: Subgroup analysis of a phase I/II study.

Swetha Kambhampati Thiruvengadam, Leslie L Popplewell, Alex F Herrera

|Oct 27, 2025

Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.

Edward R Scheffer Cliff, Guido D Pelaez, Fei Wan

|Oct 10, 2025

Real-world experience with CAR-T therapy in relapsed and refractory follicular lymphoma.

Nicolás Triantafilo, Arnab Chowdhury, Swetha Thiruvengadam

Pageof 5

Frequent Collaborators

Alex F Herrera

Ibrahim Aldoss

Tamer Othman

Lihua E Budde

John H Baird

Haris Ali

Paul Koller

Ryotaro Nakamura

Shin Yeu Ong

Saro H Armenian

Frequent Collaborators

Alex F Herrera

Ibrahim Aldoss

Tamer Othman

Lihua E Budde